Subscribe to RSS
DOI: 10.1055/a-2595-5575
Patient Care Pathways and Risk Assessments in Patients with Atrial Fibrillation: A Comparison of Asian versus Non-Asian Cohorts

Abstract
Patient care pathways provide an integrated care approach to atrial fibrillation (AF) management. International guidelines propose various patient care pathways, each emphasizing different strategies for assessing stroke and bleeding risk. Due to different ethnicities and susceptibility to stroke or bleeding risk, caution should be taken during application of Western cohorts-derived patient care pathways to Asian cohorts. Evidence-based rather than eminence-based strategies should be adopted for AF patient care. In this clinical focus, we summarize and compare patient care pathways, using evidence on the implementation in real-world registries, and strategies for assessing stroke and bleeding risk across Asian and non-Asian guidelines.
Keywords
atrial fibrillation - patient care pathway - stroke prevention - bleeding risk score - Asian - non-Asian guidelinesPublication History
Received: 23 January 2025
Accepted: 27 April 2025
Article published online:
20 May 2025
© 2025. Thieme. All rights reserved.
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
References
- 1 Linz D, Gawalko M, Betz K. et al. Atrial fibrillation: epidemiology, screening and digital health. Lancet Reg Health Eur 2024; 37: 100786
- 2 Wong CX, Tse HF, Choi EK. et al. The burden of atrial fibrillation in the Asia-Pacific region. Nat Rev Cardiol 2024; 21 (12) 841-843
- 3 Chao TF, Liu CJ, Tuan TC. et al. Lifetime risks, projected numbers, and adverse outcomes in Asian patients with atrial fibrillation: a report from the Taiwan nationwide AF cohort study. Chest 2018; 153 (02) 453-466
- 4 Kim D, Yang PS, Jang E. et al. 10-year nationwide trends of the incidence, prevalence, and adverse outcomes of non-valvular atrial fibrillation nationwide health insurance data covering the entire Korean population. Am Heart J 2018; 202: 20-26
- 5 Bai Y, Wang YL, Shantsila A, Lip GYH. The global burden of atrial fibrillation and stroke: a systematic review of the clinical epidemiology of atrial fibrillation in Asia. Chest 2017; 152 (04) 810-820
- 6 Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol 2017; 14 (11) 627-628
- 7 Chao TF, Joung B, Takahashi Y. et al. 2021 focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation: executive summary. Thromb Haemost 2022; 122 (01) 20-47
- 8 Joglar JA, Chung MK, Armbruster AL. et al; Writing Committee Members. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2024; 83 (01) 109-279
- 9 Van Gelder IC, Rienstra M, Bunting KV. et al; ESC Scientific Document Group. 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2024; 45 (36) 3314-3414
- 10 Wang Y, Guo Y, Qin M. et al; Expert Reviewers. 2024 Chinese expert consensus guidelines on the diagnosis and treatment of atrial fibrillation in the elderly, endorsed by Geriatric Society of Chinese Medical Association (Cardiovascular Group) and Chinese Society of Geriatric Health Medicine (Cardiovascular Branch): executive summary. Thromb Haemost 2024; 124 (10) 897-911
- 11 Potpara T, Romiti GF, Sohns C. The 2024 European Society of Cardiology guidelines for diagnosis and management of atrial fibrillation: a viewpoint from a practicing clinician's perspective. Thromb Haemost 2024; 124 (12) 1087-1094
- 12 Romiti GF, Corica B, Proietti M. et al; GLORIA-AF Investigators. Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry. EClinicalMedicine 2023; 63: 102039
- 13 Chao TF, Lip GYH, Liu CJ. et al. Relationship of aging and incident comorbidities to stroke risk in patients with atrial fibrillation. J Am Coll Cardiol 2018; 71 (02) 122-132
- 14 Chao TF, Liao JN, Tuan TC. et al. Incident co-morbidities in patients with atrial fibrillation initially with a CHA2DS2-VASc score of 0 (males) or 1 (females): implications for reassessment of stroke risk in initially “low-risk” patients. Thromb Haemost 2019; 119 (07) 1162-1170
- 15 Proietti M, Romiti GF, Olshansky B, Lane DA, Lip GYH. Improved outcomes by integrated care of anticoagulated patients with atrial fibrillation using the simple ABC (Atrial fibrillation Better Care) pathway. Am J Med 2018; 131 (11) 1359-1366.e6
- 16 Yoon M, Yang PS, Jang E. et al. Improved population-based clinical outcomes of patients with atrial fibrillation by compliance with the simple ABC (Atrial fibrillation Better Care) pathway for integrated care management: a nationwide cohort study. Thromb Haemost 2019; 119 (10) 1695-1703
- 17 Stevens D, Harrison SL, Kolamunnage-Dona R, Lip GYH, Lane DA. The Atrial fibrillation Better Care pathway for managing atrial fibrillation: a review. Europace 2021; 23 (10) 1511-1527
- 18 Romiti GF, Pastori D, Rivera-Caravaca JM. et al. Adherence to the “Atrial fibrillation Better Care” pathway in patients with atrial fibrillation: impact on clinical outcomes—a systematic review and meta-analysis of 285,000 patients. Thromb Haemost 2022; 122 (03) 406-414
- 19 Bucci T, Proietti M, Shantsila A. et al; APHRS-AF Registry Investigators. Integrated care for atrial fibrillation using the ABC pathway in the prospective APHRS-AF registry. JACC Asia 2023; 3 (04) 580-591
- 20 Guo Y, Lane DA, Wang L. et al; mAF-App II Trial Investigators. Mobile health technology to improve care for patients with atrial fibrillation. J Am Coll Cardiol 2020; 75 (13) 1523-1534
- 21 Li M, Chu M, Shen Y. et al; MIRACLE-AF Trial Investigators. A novel model of integrated care of older patients with atrial fibrillation in rural China. JACC Asia 2024; 4 (10) 764-773
- 22 Chu M, Zhang S, Gong J. et al; MIRACLE-AF Investigators. Telemedicine-based integrated management of atrial fibrillation in village clinics: a cluster randomized trial. Nat Med 2025; 31 (04) 1276-1285
- 23 Johnsen SP, Proietti M, Maggioni AP, Lip GYH. A multinational European network to implement integrated care in elderly multimorbid atrial fibrillation patients: the AFFIRMO Consortium. Eur Heart J 2022; 43 (31) 2916-2918
- 24 Luo X, Xu W, Ming WK. et al. Cost-effectiveness of mobile health-based integrated care for atrial fibrillation: model development and data analysis. J Med Internet Res 2022; 24 (04) e29408
- 25 Camacho EM, Lip GYH. Estimating the impact of implementing an integrated care management approach with Atrial fibrillation Better Care (ABC) pathway for patients with atrial fibrillation in England from 2020 to 2040. Eur Heart J Qual Care Clin Outcomes 2024; 10 (04) 326-333
- 26 Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010; 137 (02) 263-272
- 27 Xiong Q, Chen S, Senoo K, Proietti M, Hong K, Lip GY. The CHADS2 and CHA2DS2-VASc scores for predicting ischemic stroke among East Asian patients with atrial fibrillation: a systemic review and meta-analysis. Int J Cardiol 2015; 195: 237-242
- 28 Chao TF, Liu CJ, Tuan TC. et al. Comparisons of CHADS2 and CHA2DS2-VASc scores for stroke risk stratification in atrial fibrillation: which scoring system should be used for Asians?. Heart Rhythm 2016; 13 (01) 46-53
- 29 Kang SH, Choi EK, Han KD. et al. Risk of ischemic stroke in patients with non-valvular atrial fibrillation not receiving oral anticoagulants—Korean nationwide population-based study. Circ J 2017; 81 (08) 1158-1164
- 30 Kim TH, Yang PS, Uhm JS. et al. CHA2DS2-VASc score (congestive heart failure, hypertension, age ≥75 [doubled], diabetes mellitus, prior stroke or transient ischemic attack [doubled], vascular disease, age 65-74, female) for stroke in Asian patients with atrial fibrillation: a Korean nationwide sample cohort study. Stroke 2017; 48 (06) 1524-1530
- 31 Corica B, Lobban T, True Hills M, Proietti M, Romiti GF. Sex as a risk factor for atrial fibrillation-related stroke. Thromb Haemost 2024; 124 (04) 281-285
- 32 Nielsen PB, Skjøth F, Overvad TF, Larsen TB, Lip GYH. Female sex is a risk modifier rather than a risk factor for stroke in atrial fibrillation: should we use a CHA2DS2-VA score rather than CHA2DS2-VASc?. Circulation 2018; 137 (08) 832-840
- 33 Lip GYH, Teppo K, Nielsen PB. CHA2DS2-VASc or a non-sex score (CHA2DS2-VA) for stroke risk prediction in atrial fibrillation: contemporary insights and clinical implications. Eur Heart J 2024; 45 (36) 3718-3720
- 34 Chao TF, Lip GYH, Lin YJ. et al. Age threshold for the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation: insights into the optimal assessment of age and incident comorbidities. Eur Heart J 2019; 40 (19) 1504-1514
- 35 Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138 (05) 1093-1100
- 36 Gage BF, Yan Y, Milligan PE. et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151 (03) 713-719
- 37 Fang MC, Go AS, Chang Y. et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011; 58 (04) 395-401
- 38 Gorog DA, Gue YX, Chao TF. et al. Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: executive summary of a European and Asia-Pacific expert consensus paper. Thromb Haemost 2022; 122 (10) 1625-1652
- 39 Kang DS, Yang PS, Kim D. et al. Racial differences in ischemic and hemorrhagic stroke: an ecological epidemiological study. Thromb Haemost 2024; 124 (09) 883-892
- 40 Kang DS, Yang PS, Kim D. et al. Racial differences in bleeding risk: an ecological epidemiological study comparing Korea and United Kingdom subjects. Thromb Haemost 2024; 124 (09) 842-851
- 41 Kim HK, Tantry US, Smith Jr SC. et al. The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb Haemost 2021; 121 (04) 422-432
- 42 Gao X, Cai X, Yang Y, Zhou Y, Zhu W. Diagnostic accuracy of the HAS-BLED bleeding score in VKA- or DOAC-treated patients with atrial fibrillation: a systematic review and meta-analysis. Front Cardiovasc Med 2021; 8: 757087
- 43 Pastori D, Marang A, Bisson A, Herbert J, Lip GYH, Fauchier L. Performance of the HAS-BLED, ORBIT, and ATRIA bleeding risk scores on a cohort of 399 344 hospitalized patients with atrial fibrillation and cancer: data from the French national hospital discharge database. J Am Heart Assoc 2022; 11 (23) e026388
- 44 Guo Y, Zhu H, Chen Y, Lip GYH. Comparing bleeding risk assessment focused on modifiable risk factors only versus validated bleeding risk scores in atrial fibrillation. Am J Med 2018; 131 (02) 185-192
- 45 Esteve-Pastor MA, Rivera-Caravaca JM, Shantsila A, Roldán V, Lip GYH, Marín F. Assessing bleeding risk in atrial fibrillation patients: comparing a bleeding risk score based only on modifiable bleeding risk factors against the HAS-BLED score. The AMADEUS trial. Thromb Haemost 2017; 117 (12) 2261-2266
- 46 Serna MJ, Rivera-Caravaca JM, López-Gálvez R. et al. Dynamic assessment of CHA2DS2-VASc and HAS-BLED scores for predicting ischemic stroke and major bleeding in atrial fibrillation patients. Rev Esp Cardiol (Engl Ed) 2024; 77 (10) 835-842
- 47 Caldeira D, Costa J, Fernandes RM, Pinto FJ, Ferreira JJ. Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysis. J Interv Card Electrophysiol 2014; 40 (03) 277-284
- 48 Proietti M, Romiti GF, Vitolo M, Potpara TS, Boriani G, Lip GYH. Comparison of HAS-BLED and ORBIT bleeding risk scores in atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants: a report from the ESC-EHRA EORP-AF General Long-Term Registry. Eur Heart J Qual Care Clin Outcomes 2022; 8 (07) 778-786
- 49 Apostolakis S, Lane DA, Guo Y, Buller H, Lip GY. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol 2012; 60 (09) 861-867
- 50 Guo Y, Lane DA, Chen Y, Lip GYH. mAF-App II Trial investigators. Regular bleeding risk assessment associated with reduction in bleeding outcomes: the mAFA-II randomized trial. Am J Med 2020; 133 (10) 1195-1202.e2
- 51 Chao TF, Chan YH, Tuan TC. et al. Should oral anticoagulants still be prescribed to patients with atrial fibrillation with a single stroke risk factor but at high bleeding risk? A nationwide cohort study. Eur Heart J Qual Care Clin Outcomes 2022; 8 (05) 588-595
- 52 Nelson WW, Laliberté F, Patel AA. et al. Stroke risk reduction outweighed bleeding risk increase from vitamin K antagonist treatment among nonvalvular atrial fibrillation patients with high stroke risk and low bleeding risk. Curr Med Res Opin 2017; 33 (04) 631-638
- 53 Hijazi Z, Lindbäck J, Oldgren J. et al. Individual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC-AF risk scores. Am Heart J 2023; 261: 55-63
- 54 Aggarwal R, Ruff CT, Virdone S. et al. Development and validation of the DOAC score: a novel bleeding risk prediction tool for patients with atrial fibrillation on direct-acting oral anticoagulants. Circulation 2023; 148 (12) 936-946
- 55 Mei DA, Imberti JF, Bonini N. et al. Performance of HAS-BLED and DOAC scores to predict major bleeding events in atrial fibrillation patients treated with direct oral anticoagulants: a report from a prospective European observational registry. Eur J Intern Med 2024; 128: 63-70
- 56 Fan M, Yin X, Jin Y, Zheng X, Zhu S. Assessing the applicability of the DOAC, HAS-BLED and ORBIT risk scores in Chinese patients on non-vitamin K antagonist oral anticoagulants. Br J Clin Pharmacol 2025; (e-pub ahead of print).